Alpha CD20-IgG1-huEndoP125A
Alternative Names: αCD20-IgG1-huEndoP125ALatest Information Update: 06 Jun 2023
At a glance
- Originator Synergys Biotherapeutics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Endostatin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mantle-cell lymphoma